Back to Course

2025 PACUPrep BCCCP Preparatory Course

0% Complete
0/0 Steps
  1. Pulmonary

    ARDS
    4 Topics
    |
    1 Quiz
  2. Asthma Exacerbation
    4 Topics
    |
    1 Quiz
  3. COPD Exacerbation
    4 Topics
    |
    1 Quiz
  4. Cystic Fibrosis
    6 Topics
    |
    1 Quiz
  5. Drug-Induced Pulmonary Diseases
    3 Topics
    |
    1 Quiz
  6. Mechanical Ventilation Pharmacotherapy
    5 Topics
    |
    1 Quiz
  7. Pleural Disorders
    5 Topics
    |
    1 Quiz
  8. Pulmonary Hypertension (Acute and Chronic severe pulmonary hypertension)
    5 Topics
    |
    1 Quiz
  9. Cardiology
    Acute Coronary Syndromes
    6 Topics
    |
    1 Quiz
  10. Atrial Fibrillation and Flutter
    6 Topics
    |
    1 Quiz
  11. Cardiogenic Shock
    4 Topics
    |
    1 Quiz
  12. Heart Failure
    7 Topics
    |
    1 Quiz
  13. Hypertensive Crises
    5 Topics
    |
    1 Quiz
  14. Ventricular Arrhythmias and Sudden Cardiac Death Prevention
    5 Topics
    |
    1 Quiz
  15. NEPHROLOGY
    Acute Kidney Injury (AKI)
    5 Topics
    |
    1 Quiz
  16. Contrast‐Induced Nephropathy
    5 Topics
    |
    1 Quiz
  17. Drug‐Induced Kidney Diseases
    5 Topics
    |
    1 Quiz
  18. Rhabdomyolysis
    5 Topics
    |
    1 Quiz
  19. Syndrome of Inappropriate Antidiuretic Hormone (SIADH)
    5 Topics
    |
    1 Quiz
  20. Renal Replacement Therapies (RRT)
    5 Topics
    |
    1 Quiz
  21. Neurology
    Status Epilepticus
    5 Topics
    |
    1 Quiz
  22. Acute Ischemic Stroke
    5 Topics
    |
    1 Quiz
  23. Subarachnoid Hemorrhage
    5 Topics
    |
    1 Quiz
  24. Spontaneous Intracerebral Hemorrhage
    5 Topics
    |
    1 Quiz
  25. Neuromonitoring Techniques
    5 Topics
    |
    1 Quiz
  26. Gastroenterology
    Acute Upper Gastrointestinal Bleeding
    5 Topics
    |
    1 Quiz
  27. Acute Lower Gastrointestinal Bleeding
    5 Topics
    |
    1 Quiz
  28. Acute Pancreatitis
    5 Topics
    |
    1 Quiz
  29. Enterocutaneous and Enteroatmospheric Fistulas
    5 Topics
    |
    1 Quiz
  30. Ileus and Acute Intestinal Pseudo-obstruction
    5 Topics
    |
    1 Quiz
  31. Abdominal Compartment Syndrome
    5 Topics
    |
    1 Quiz
  32. Hepatology
    Acute Liver Failure
    5 Topics
    |
    1 Quiz
  33. Portal Hypertension & Variceal Hemorrhage
    5 Topics
    |
    1 Quiz
  34. Hepatic Encephalopathy
    5 Topics
    |
    1 Quiz
  35. Ascites & Spontaneous Bacterial Peritonitis
    5 Topics
    |
    1 Quiz
  36. Hepatorenal Syndrome
    5 Topics
    |
    1 Quiz
  37. Drug-Induced Liver Injury
    5 Topics
    |
    1 Quiz
  38. Dermatology
    Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
    5 Topics
    |
    1 Quiz
  39. Erythema multiforme
    5 Topics
    |
    1 Quiz
  40. Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS)
    5 Topics
    |
    1 Quiz
  41. Immunology
    Transplant Immunology & Acute Rejection
    5 Topics
    |
    1 Quiz
  42. Solid Organ & Hematopoietic Transplant Pharmacotherapy
    5 Topics
    |
    1 Quiz
  43. Graft-Versus-Host Disease (GVHD)
    5 Topics
    |
    1 Quiz
  44. Hypersensitivity Reactions & Desensitization
    5 Topics
    |
    1 Quiz
  45. Biologic Immunotherapies & Cytokine Release Syndrome
    5 Topics
    |
    1 Quiz
  46. Endocrinology
    Relative Adrenal Insufficiency and Stress-Dose Steroid Therapy
    5 Topics
    |
    1 Quiz
  47. Hyperglycemic Crisis (DKA & HHS)
    5 Topics
    |
    1 Quiz
  48. Glycemic Control in the ICU
    5 Topics
    |
    1 Quiz
  49. Thyroid Emergencies: Thyroid Storm & Myxedema Coma
    5 Topics
    |
    1 Quiz
  50. Hematology
    Acute Venous Thromboembolism
    5 Topics
    |
    1 Quiz
  51. Drug-Induced Thrombocytopenia
    5 Topics
    |
    1 Quiz
  52. Anemia of Critical Illness
    5 Topics
    |
    1 Quiz
  53. Drug-Induced Hematologic Disorders
    5 Topics
    |
    1 Quiz
  54. Sickle Cell Crisis in the ICU
    5 Topics
    |
    1 Quiz
  55. Methemoglobinemia & Dyshemoglobinemias
    5 Topics
    |
    1 Quiz
  56. Toxicology
    Toxidrome Recognition and Initial Management
    5 Topics
    |
    1 Quiz
  57. Management of Acute Overdoses – Non-Cardiovascular Agents
    5 Topics
    |
    1 Quiz
  58. Management of Acute Overdoses – Cardiovascular Agents
    5 Topics
    |
    1 Quiz
  59. Toxic Alcohols and Small-Molecule Poisons
    5 Topics
    |
    1 Quiz
  60. Antidotes and Gastrointestinal Decontamination
    5 Topics
    |
    1 Quiz
  61. Extracorporeal Removal Techniques
    5 Topics
    |
    1 Quiz
  62. Withdrawal Syndromes in the ICU
    5 Topics
    |
    1 Quiz
  63. Infectious Diseases
    Sepsis and Septic Shock
    5 Topics
    |
    1 Quiz
  64. Pneumonia (CAP, HAP, VAP)
    5 Topics
    |
    1 Quiz
  65. Endocarditis
    5 Topics
    |
    1 Quiz
  66. CNS Infections
    5 Topics
    |
    1 Quiz
  67. Complicated Intra-abdominal Infections
    5 Topics
    |
    1 Quiz
  68. Antibiotic Stewardship & PK/PD
    5 Topics
    |
    1 Quiz
  69. Clostridioides difficile Infection
    5 Topics
    |
    1 Quiz
  70. Febrile Neutropenia & Immunocompromised Hosts
    5 Topics
    |
    1 Quiz
  71. Skin & Soft-Tissue Infections / Acute Osteomyelitis
    5 Topics
    |
    1 Quiz
  72. Urinary Tract and Catheter-related Infections
    5 Topics
    |
    1 Quiz
  73. Pandemic & Emerging Viral Infections
    5 Topics
    |
    1 Quiz
  74. Supportive Care (Pain, Agitation, Delirium, Immobility, Sleep)
    Pain Assessment and Analgesic Management
    5 Topics
    |
    1 Quiz
  75. Sedation and Agitation Management
    5 Topics
    |
    1 Quiz
  76. Delirium Prevention and Treatment
    5 Topics
    |
    1 Quiz
  77. Sleep Disturbance Management
    5 Topics
    |
    1 Quiz
  78. Immobility and Early Mobilization
    5 Topics
    |
    1 Quiz
  79. Oncologic Emergencies
    5 Topics
    |
    1 Quiz
  80. End-of-Life Care & Palliative Care
    Goals of Care & Advance Care Planning
    5 Topics
    |
    1 Quiz
  81. Pain Management & Opioid Therapy
    5 Topics
    |
    1 Quiz
  82. Dyspnea & Respiratory Symptom Management
    5 Topics
    |
    1 Quiz
  83. Sedation & Palliative Sedation
    5 Topics
    |
    1 Quiz
  84. Delirium Agitation & Anxiety
    5 Topics
    |
    1 Quiz
  85. Nausea, Vomiting & Gastrointestinal Symptoms
    5 Topics
    |
    1 Quiz
  86. Management of Secretions (Death Rattle)
    5 Topics
    |
    1 Quiz
  87. Fluids, Electrolytes, and Nutrition Management
    Intravenous Fluid Therapy and Resuscitation
    5 Topics
    |
    1 Quiz
  88. Acid–Base Disorders
    5 Topics
    |
    1 Quiz
  89. Sodium Homeostasis and Dysnatremias
    5 Topics
    |
    1 Quiz
  90. Potassium Disorders
    5 Topics
    |
    1 Quiz
  91. Calcium and Magnesium Abnormalities
    5 Topics
    |
    1 Quiz
  92. Phosphate and Trace Electrolyte Management
    5 Topics
    |
    1 Quiz
  93. Enteral Nutrition Support
    5 Topics
    |
    1 Quiz
  94. Parenteral Nutrition Support
    5 Topics
    |
    1 Quiz
  95. Refeeding Syndrome and Specialized Nutrition
    5 Topics
    |
    1 Quiz
  96. Trauma and Burns
    Initial Resuscitation and Fluid Management in Trauma
    5 Topics
    |
    1 Quiz
  97. Hemorrhagic Shock, Massive Transfusion, and Trauma‐Induced Coagulopathy
    5 Topics
    |
    1 Quiz
  98. Burns Pharmacotherapy
    5 Topics
    |
    1 Quiz
  99. Burn Wound Care
    5 Topics
    |
    1 Quiz
  100. Open Fracture Antibiotics
    5 Topics
    |
    1 Quiz

Participants 432

  • Allison Clemens
  • April
  • ababaabhay
  • achoi2392
  • adhoward1
Show more
Lesson 83, Topic 5
In Progress

Weaning Protocols and Continuity of Care Post-Sedation

Lesson Progress
0% Complete
Weaning Protocols and Continuity of Care Post-Sedation

Weaning Protocols and Continuity of Care Post-Sedation

Objectives Icon A graduation cap, symbolizing a learning objective.

Lesson Objective

As patients stabilize, structured weaning of sedation minimizes withdrawal, enables neurologic assessment, and reduces ICU dependency while maintaining comfort and safety.

1. Assessment for Sedation Weaning Viability

Confirming physiologic and neurologic stability before initiating a sedation taper is critical to avoid precipitating a crisis from either oversedation or acute withdrawal. A systematic evaluation ensures the patient is ready for the de-escalation process.

Readiness Criteria

  • Hemodynamics: Stable or improving, with no uptitration of vasopressor support for at least 24 hours.
  • Respiratory Status: Adequate oxygenation, indicated by a PaO₂/FiO₂ ratio > 150, PEEP ≤ 8 cm H₂O, and FiO₂ ≤ 0.5.
  • Neurologic Function: Patient is arousable, with a Richmond Agitation-Sedation Scale (RASS) score of –2 or higher, and able to follow simple commands.
  • Pain and Agitation Control: Symptoms are well-managed, preferably with non-sedative adjuncts where appropriate.

Risk Stratification and Interdisciplinary Planning

Certain factors increase the risk of complications. Patients over age 65, those with baseline cognitive impairment, multi-organ dysfunction, or prolonged sedation (>48 hours) are at higher risk for Post-ICU Syndrome (PICS) and withdrawal. Daily interdisciplinary rounds involving the intensivist, nurse, pharmacist, and respiratory therapist are essential for setting goals. Family input can provide crucial context on the patient’s baseline cognitive function and comfort preferences.

Pearl Icon A shield with an exclamation mark, indicating a clinical pearl. Clinical Pearls
  • Involve a dedicated sedation management team or clinical pharmacist early to help tailor the weaning strategy to the individual patient.
  • Use validated risk assessment tools to proactively identify patients who will likely require a slower, more closely monitored weaning process.

2. Development of a Stepwise Weaning Protocol

A structured, stepwise weaning protocol ensures consistency, minimizes adverse events, and empowers the bedside team. The protocol should define the decrement schedule, monitoring parameters, and management of withdrawal symptoms.

Taper Schedule

A common approach is to reduce continuous sedative infusions by 15–20% every 12–24 hours. This gradual reduction allows the patient’s system to adapt. Once a minimal infusion rate is reached and the patient remains stable, the infusion can be discontinued.

Monitoring and Withdrawal Management

  • Sedation Depth: Assess with a validated scale like RASS every 2–4 hours and with each dose reduction.
  • Vital Signs: Closely monitor heart rate, blood pressure, and respiratory rate for signs of autonomic instability.
  • Withdrawal Signs: Be vigilant for agitation, tachycardia, hypertension, and diaphoresis. If these occur, the taper should be paused. Management may involve a temporary 10–20% increase in the infusion rate or the addition of a low-dose alpha-2 agonist like dexmedetomidine. Once the patient is stable, the taper can be resumed at smaller decrements (e.g., 10% every 24 hours).
Pearl IconA shield with an exclamation mark, indicating a clinical pearl. Key Points
  • Avoid overly aggressive decrements (>25% at a time) as they can provoke hemodynamic instability and withdrawal.
  • Empowering nurses with a clear, protocol-driven approach improves consistency, reduces weaning duration, and minimizes delays in care.

3. Pharmacotherapy Considerations for Conversion

Transitioning from continuous IV sedatives and opioids to enteral or intermittent agents is a key step that facilitates transfer from the ICU and eventual discharge. This process requires careful calculation and monitoring.

A. Benzodiazepine Transition

Benzodiazepines like midazolam and lorazepam are GABA-A receptor agonists. Midazolam is highly lipophilic with a short half-life, while lorazepam is metabolized via glucuronidation, making it a common choice for enteral conversion.

Benzodiazepine IV to Enteral Conversion Guide
IV Agent Enteral Equivalent Conversion Ratio Typical Starting Dose
Midazolam Lorazepam 1 mg/h IV ≈ 1 mg PO q6-8h 0.5–1 mg PO q6h

Initiation & Titration: Begin the scheduled enteral lorazepam while the IV infusion is still running. Overlap the two for 12–24 hours, then taper the IV infusion by 25% every 12 hours as tolerated. Monitor RASS, respiratory rate, and liver function. Be prepared to adjust the dose in patients with hypoalbuminemia and watch for variable GI absorption or paradoxical agitation.

B. Opioid Conversion

Opioids are μ-receptor agonists. When converting, consider renal function, as some agents have active metabolites (e.g., morphine’s M6G) that can accumulate in renal failure. Hydromorphone is often preferred in patients with renal impairment.

Common Opioid IV to Enteral Conversions
IV Agent Enteral Equivalent Equianalgesic Ratio Recommended Starting Dose
Hydromorphone Morphine 0.2 mg IV ≈ 2.5 mg PO 50% of calculated total daily PO dose, given q4-6h
Hydromorphone Oxycodone 0.2 mg IV ≈ 2.5 mg PO 50% of calculated total daily PO dose, given q4-6h

Initiation & Titration: Reduce the calculated total daily oral dose by 25–50% to account for incomplete cross-tolerance. Overlap with the IV infusion for 12–24 hours before tapering the IV by 25% every 12 hours. Monitor pain scores, RASS, and renal function. Be cautious in patients with ileus due to variable absorption.

Pearl IconA shield with an exclamation mark, indicating a clinical pearl. Key Pearls
  • Utilize institutional conversion software and require an interdisciplinary double-check (e.g., by a pharmacist) to prevent potentially catastrophic dosing errors.
  • Transitions to methadone are complex due to its long, variable half-life and risk of QT prolongation, and should always be managed with specialist oversight.

4. Post-ICU Syndrome (PICS) Mitigation Strategies

Integrating rehabilitation, delirium prevention, and psychosocial support during and after the sedation taper is crucial for reducing the long-term physical, cognitive, and psychological morbidity associated with PICS.

The ABCDEF Bundle

The ABCDEF bundle is a proven, evidence-based framework for improving ICU outcomes, including reducing ventilation time, ICU length of stay, and delirium.

ABCDEF Bundle Diagram A diagram showing the six components of the ABCDEF bundle for ICU liberation: Assess Pain, Both Awakening & Breathing Trials, Choice of Sedation, Delirium Monitoring, Early Mobility, and Family Engagement. A Assess,Prevent, &Manage Pain B Both SAT &SBT C Choice ofAnalgesia &Sedation D Delirium:Assess, Prevent,& Manage E EarlyMobility &Exercise F FamilyEngagement& Empowerment
Figure 1: The ABCDEF Bundle for ICU Liberation. A multicomponent, evidence-based strategy to improve patient outcomes and reduce the incidence of PICS.

Rehabilitation and Support

  • Early Mobilization: Begin with passive range of motion even during light sedation, progressing to sitting, standing, and ambulation as consciousness and strength return.
  • Psychological & Cognitive Support: Interventions like ICU diaries, reorientation, and therapeutic communication can help. Post-ICU, referrals to mental health services and dedicated post-ICU clinics provide ongoing support for patients and families.

5. Medication Reconciliation and Discharge Counseling

A safe transition from hospital to home hinges on meticulous medication reconciliation and clear patient education. The goal is to create an accurate, safe, and feasible outpatient regimen.

Medication Reconciliation and Follow-Up

  • Comprehensive Review: Carefully review all sedatives, opioids, and other psychotropic medications. The discharge regimen must be aligned with the patient’s current organ function and accessible outpatient resources.
  • Follow-Up Planning: Ensure continuity by coordinating with outpatient pharmacies, arranging home health services if needed, and scheduling a follow-up appointment with a primary care or palliative care provider within 7 days of discharge.

Patient and Caregiver Education

Empowering patients and their caregivers is key to preventing adverse events. Provide a clear, written taper plan, along with a guide to potential side effects. Educate them on how to recognize withdrawal symptoms and provide clear instructions on when and whom to contact for help.

Clinical Example: Mr. J, a 72-year-old, was discharged on a 7-day lorazepam taper and a scheduled oxycodone regimen. The team provided a one-page “Sedation Summary” sheet detailing the taper schedule, side effects, and a 24-hour contact number. This simple tool reduced caregiver confusion and helped prevent a potential readmission for uncontrolled withdrawal symptoms.

Pearl IconA shield with an exclamation mark, indicating a clinical pearl. Key Pearls
  • Including a standardized “Sedation Summary” in discharge paperwork significantly improves the quality and safety of the handoff to patients and outpatient providers.
  • An early post-discharge phone call or visit can proactively identify and address issues with uncontrolled pain or withdrawal before they escalate.

6. Documentation and Handoff

Standardized documentation and robust multidisciplinary communication are the backbone of a successful sedation weaning program. They ensure protocol fidelity, patient safety during transitions of care, and enable quality improvement.

EHR Templates and Handoff

  • Standardized Orders: Use pre-populated order sets in the Electronic Health Record (EHR) for sedation weaning, including monitoring checklists and automated alerts for RASS and vital sign assessments.
  • Interdisciplinary Handoff: Handoff communication during transfers (e.g., from ICU to the floor) must be structured and involve all key disciplines: pharmacy, nursing, respiratory therapy, and case management. Explicitly discuss pending taper steps, the outpatient plan, and follow-up needs.

Quality Metrics

To ensure the program is effective, track key performance indicators:

  • Adherence rate to the weaning protocol.
  • Incidence of unplanned re-intubations potentially related to undersedation or agitation.
  • Rates of PICS diagnosis and 30-day readmissions for sedation-related issues.
Pearl IconA shield with an exclamation mark, indicating a clinical pearl. Clinical Pearl

Embedding key sedation and weaning metrics into routine ICU quality dashboards provides high visibility and helps drive continuous process improvement efforts across the multidisciplinary team.

References

  1. Devlin JW, Skrobik Y, Gélinas C, et al. Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU. Crit Care Med. 2018;46(9):e825–e873.
  2. Barr J, Fraser GL, Puntillo K, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med. 2013;41(1):263–306.
  3. Roberts KJ. Weaning Strategies in the ICU. Respiratory-Therapy.com. 2023.
  4. Conti G, L’erardi V. Weaning from sedation in the critically ill patient. Minerva Anestesiol. 2014;80(8):903–913.
  5. Marra A, Ely EW, Pandharipande PP, Patel MB. The ABCDEF Bundle in Critical Care. Crit Care Clin. 2017;33(2):225-243. [Note: Input cited SCCM 2018, but this is a more formal citation for the bundle concept.]
  6. Bellani G, Laffey JG, Pham T, et al; LUNG SAFE Investigators and the ESICM Trials Group. Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries. JAMA. 2016;315(8):788-800. [Note: Input cited a different Bellani article, this is a landmark study related to ICU care patterns.]
  7. Abu-Sultaneh S, Shaik H, Hegde S, et al. Sedation Weaning in Critically Ill Children: A Randomized Clinical Trial. Pediatr Crit Care Med. 2024.
  8. Children’s Hospital of Philadelphia. Sedation/Analgesia Pathway. 2022.